Trial Profile
A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Trazpiroben (Primary) ; Metoclopramide
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 20 Jun 2021 Results assessing the safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function) of twice-daily trazpiroben (5, 25 and 100 mg) in participants with gastroparesis, published in the Alimentary Pharmacology and Therapeutics.
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Mar 2018 Planned End Date changed from 9 Mar 2018 to 10 Mar 2018.